{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:50:36Z","timestamp":1788371436947,"version":"build-2803163510"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Valganciclovir (2\/d) therapy for 6 months in neonates with symptomatic congenital cytomegalovirus (cCMV) infection improves hearing and neurodevelopmental outcome. The only reported adverse event was neutropenia. Since 2009, our protocol for symptomatic cCMV infection was a 1-year treatment of 2\/d for the first 3 months followed by 9 months of 1\/d.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective study. Infants with cCMV treated with valganciclovir for 1 year were recruited. Data of drug-related hematologic adverse events were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>One hundred sixty infants were eligible; 46 (28.8%) had experienced at least 1 episode of neutropenia (58 episodes), the majority (39\/46, 84.8%) during the first 3 months of treatment and 7 (15.2%) during the last 9 months of treatment. Grades 3 and 4 neutropenia occurred in 9 (5.6%) children, almost exclusively during the first 3 months of treatment. Anemia (hemoglobin &lt;9\u2009g\/dL) was recorded in 12 (7.5%) children during the first 3 months of 2\/d treatment. Four children presented with hemoglobin levels &lt;7\u2009g\/dL and needed a blood transfusion. One child was diagnosed with transient pure red cell aplasia. No long-term adverse events were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Although prolonged valganciclovir treatment for cCMV is safe, a close monitoring of the white blood cell count and hemoglobin levels is warranted. Much lower rates of grades 3 and 4 neutropenia were observed than previously reported, probably owing to our unique treatment protocol. Nevertheless, drug-induced anemia should be of primary concern. The optimal protocol assessing clinical outcome, concurrently with potential side effects, has not yet been determined.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000002079","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T18:10:07Z","timestamp":1524247807000},"page":"127-130","source":"Crossref","is-referenced-by-count":29,"title":["Hematologic Adverse Events Associated With Prolonged Valganciclovir Treatment in Congenital Cytomegalovirus Infection"],"prefix":"10.1097","volume":"38","author":[{"given":"Liron","family":"Ziv","sequence":"first","affiliation":[{"name":"Department of Pediatrics A"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Yacobovich","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Schneider Children\u2019s Medical Center, Petah Tiqva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Pardo","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"Department of Gynecology and Obstetrics, Helen Schneider Hospital for Women, Rabin Medical Center, Beilinson Hospital, Petah Tiqva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Havatzelet","family":"Yarden-Bilavsky","sequence":"additional","affiliation":[{"name":"Department of Pediatrics A"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Amir","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"Department of Gynecology and Obstetrics, Helen Schneider Hospital for Women, Rabin Medical Center, Beilinson Hospital, Petah Tiqva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micky","family":"Osovsky","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"Department of Neonatology, Rabin Medical Center, Beilinson Hospital, Petah Tiqva, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efraim","family":"Bilavsky","sequence":"additional","affiliation":[{"name":"Department of Pediatrics C"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection.","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev Med Virol"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1542\/peds.2014-1173","article-title":"Hearing loss and congenital CMV infection: a systematic review.","volume":"134","author":"Goderis","year":"2014","journal-title":"Pediatrics"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cid\/ciw237","article-title":"Clinical implications for children born with congenital cytomegalovirus infection following a negative amniocentesis.","volume":"63","author":"Bilavsky","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease.","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N Engl J Med"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00431-010-1176-9","article-title":"Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir.","volume":"169","author":"Amir","year":"2010","journal-title":"Eur J Pediatr"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/archdischild-2015-309154","article-title":"Hearing outcome of infants with congenital cytomegalovirus and hearing impairment.","volume":"101","author":"Bilavsky","year":"2016","journal-title":"Arch Dis Child"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1111\/apa.13053","article-title":"Lenticulostriated vasculopathy is a high-risk marker for hearing loss in congenital cytomegalovirus infections.","volume":"104","author":"Bilavsky","year":"2015","journal-title":"Acta Paediatr"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1136\/adc.2010.208405","article-title":"Is lenticulostriated vasculopathy a sign of central nervous system insult in infants with congenital CMV infection?","volume":"96","author":"Amir","year":"2011","journal-title":"Arch Dis Child"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1742-5573-1-6","article-title":"WINPEPI (PEPI-for-Windows): computer programs for epidemiologists.","volume":"1","author":"Abramson","year":"2004","journal-title":"Epidemiol Perspect Innov"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jcv.2012.06.001","article-title":"Treatment of symptomatic congenital cytomegalovirus infection beyond the neonatal period.","volume":"55","author":"del Rosal","year":"2012","journal-title":"J Clin Virol"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/528376","article-title":"Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease.","volume":"197","author":"Kimberlin","year":"2008","journal-title":"J Infect Dis"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","article-title":"Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.","volume":"79","author":"Wiltshire","year":"2005","journal-title":"Transplantation"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00042560-200208010-00004","article-title":"A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis.","volume":"30","author":"Lalezari","year":"2002","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201902000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T18:40:19Z","timestamp":1694544019000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201902000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002079","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733082705.793547187","asserted-by":"object"}]},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}